CF Foundation President and CEO Robert J. Beall, Ph.D., discusses breakthrough results of the late-stage trial of VX-770, a potential therapy that treats the underlying cause of cystic fibrosis.
A new study of the combination of two potential drugs targeting the basic defect is underway for patients with the most common genetic mutation of CF, Delta F508. Lead researcher Dr. Michael Boyle explains.
